ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Considerations for disclosing Alzheimer's disease risk and biomarker results in a Pueblo community in Southwest United States.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Introduction to the special issue on ethics and equity in implementing novel biomarkers for Alzheimer's disease and related dementias: current progress and new directions.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Considerations for disclosing Alzheimer's disease risk and biomarker results in a Pueblo community in Southwest United States.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundBiomarkers and Alzheimer's disease (AD) risk disclosure may help reduce disparities in dementia diagnosis and care in Indigenous communities.
methodsSemi-structured interviews assessed beliefs about the causes of dementia, and interest in and perceived benefits and risks of obtaining AD risk information, including biomarkers.
resultsThirty-two Indigenous and 26 non-Hispanic White individuals participated in the study. The Indigenous cohort endorsed divergent beliefs about the causes of dementia relative to the non-Hispanic White cohort. Eighty-one percent of the Indigenous cohort and 100% of the non-Hispanic White cohort endorsed interest in learning their AD risk primarily to improve health behaviors, gain health knowledge, and engage in treatments or clinical trials. Indigenous participants more frequently endorsed concerns about burdening family and limited access to health care. DISCUSSION: Incorporating discussions about causes of dementia, caregiver burden, and family involvement into return-of-results procedures may support informed, collective decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.